My research focuses on tumor therapeutic resistance and tumor metastasis, in the perspective of tumor heterogeneity and tumor metabolism. I have made a series of works on the involvement of heterogeneous tumor subpopulations (CD110+, CDCP1+, TrkB+ and CD70+ subsets) in driving organ-specific metastasis and post-therapeutic recurrence. Also, I have been clarifying the essential role of various oncometabolites (lysine, methionine, uric acid, γ-aminobutyric acid, α-ketoglutaric acid and succinate), which induce signaling cascades, epigenetic remodeling and enzyme activation, during the development of tumor therapeutic resistance and distant metastasis. The intention is to provide specific diagnostic biomarkers and novel metabolic checkpoints to improve cancer outcomes in patients, and to work closely with clinicians to enable bench-to-bedside translation.